Drug Profile
OT 44
Alternative Names: OT-44Latest Information Update: 24 Nov 2020
Price :
$50
*
At a glance
- Originator Orphan Technologies
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Propionic acidaemia
Most Recent Events
- 12 Nov 2020 Orphan Technologies has been acquired by Retrophin
- 28 Aug 2020 No recent reports of development identified for research development in Propionic-acidaemia in Switzerland
- 28 Jul 2016 Early research in Propionic acidaemia in Switzerland (unspecified route)